Original Articles| Volume 46, ISSUE 12, P1649-1655, December 15, 1999

Interleukin-1β production in dysthymia before and after pharmacotherapy


      Background: Like major depression, dysthymia has been associated with elevated production of interleukin-1 (IL-1β) in mitogen-stimulated lymphocytes. In the present investigation, we assessed whether the elevated IL-1β production in dysthymic patients would normalize following treatment with sertraline.
      Methods: The production of IL-1β was determined in dysthymic patients and in nondepressed control subjects. Patients then received 12 weeks of doses of either sertraline or placebo in a double-blind trial, after which cytokine production was again determined.
      Results: Basal IL-1β was elevated in dysthymic patients relative to control subjects. Cytokine production was modestly correlated with the severity of symptoms and with the age of illness onset. Relative to placebo treatment, sertraline attenuated the symptoms of depression; however, this was not accompanied by normalization of IL-1β production.
      Conclusions: While dysthymia is associated with elevated IL-1β production, the failure for the cytokine to normalize following symptom alleviation suggests that either the IL-1β may be a trait marker of the illness, or that more sustained treatment is necessary to reduce cytokine production. Given the neuroendocrine and central neurochemical consequences of exogenously administered IL-1β, the possibility ought to be explored that increased IL-1β production may play a role in the pathophysiology of dysthymia.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Akiskal H.S
        Towards a definition of dysthymia.
        in: Burton S.W Akiskal H.S Dysthymic Disorder. Gaskell, London1990: 1-12
        • Akiskal H.S
        • Bolis C.L
        • Cazzullo C
        • Costa e Silva J.A
        • Gentil V
        • Lecrubier Y
        • et al.
        Dysthymia in neurological disorders.
        Mol Psychiatry. 1996; 1: 478-491
        • Anisman H
        • Merali Z
        Cytokines and stress in relation to anxiety and anhedonia.
        in: Dantzer R Wollmann E.E Yirmiya R Cytokines, Stress and Depression. Plenum Press, London1999: 199-234
        • Anisman H
        • Ravindran A.V
        • Griffiths J
        • Merali Z
        Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features.
        Mol Psychiat. 1999; 4: 182-188
        • Beck A.T
        • Rial W.Y
        • Rickels K
        Short form of Depression Inventory.
        Psychol Rep. 1974; 34: 1184-1186
        • Calabrese J.R
        • Skwerer R.G
        • Barna B
        • Gulledge A.D
        • Valenzuela R
        • Butkus A
        • et al.
        Depression, immunocompetence, and prostaglandins of the E series.
        Psychiatry Res. 1986; 17: 41-47
        • Dunbar P.R
        • Hill J
        • Neale T.J
        • Mellsop G.W
        Neopterin measurement provides evidence of altered cell-mediated immunity in patients with depression, but not with schizophrenia.
        Psychol Med. 1992; 22: 1051-1057
        • Dunn A.J
        Interleukin-1 as a stimulator of hormone secretion.
        Prog Neuro Endocrinimmunol. 1990; 3: 26-34
        • Dunn A.J
        Interactions between the nervous system and the immune system.
        in: Bloom F.E Kupfer D.J Psychopharmacology The Fourth Generation of Progress. Raven Press, New York1995: 719-731
        • Frommberger U.H
        • Bauer J
        • Haselbauer P
        • Fraulin A
        • Riemann D
        • Berger M
        Interleukin-6-(IL-6) plasma levels in depression and schizophrenia.
        Eur Arch Psychiatry Clin Neurosci. 1997; 247: 228-233
        • Gold P.W
        • Chrousos G.P
        • Kellner C
        • Post R.M
        • Roy A
        • Augerinas P
        Psychiatric implications of basic and clinical studies with corticotropin-releasing factor.
        Am J Psychiatry. 1984; 141: 619-627
        • Guy W
        ECDEU Assessment Manual for Psychopharmacology. NIMH, Psychopharmacology Research Branch, Bethesda, MD1976
        • Hamilton M
        Development of a rating scale for primary depressive illness.
        Br J Soc Clin Psychol. 1967; 6: 278-298
        • Holsboer F
        Neuroendocrinology of mood disorders.
        in: Bloom F.E Kupfer D.J Psychopharmacology The Fourth Generation of Progress. Raven Press, New York1995: 957-969
        • Howland R.H
        • Thas M.E
        Biological studies of dysthymia.
        Biol Psychiatry. 1991; 30: 283-304
        • Kocsis J.H
        • Thase M
        • Koran L
        • Halbreich U
        • Yonkers K
        Pharmacotherapy of pure dysthymia.
        Eur Neuropsychopharmacol. 1994; 4: S204
        • Lieb J
        • Karmali R
        Elevated levels of prostaglandin E2 and thromboxane B2 in depression.
        Prost Leukotr Med. 1983; 10: 361-368
        • Maes M
        Evidence for an immune response in major depression.
        Prog Neuropsychopharmacol Biol Psychiatry. 1995; 19: 11-38
        • Maes M
        • Bosmans E
        • De Jongh R
        • Kenis G
        • Vandoolaeghe E
        • Neels H
        Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression.
        Cytokine. 1997; 9: 853-858
        • Maes M
        • Bosmans E
        • Meltzer H.Y
        • Scharpe S
        • Suy E
        Interleukin-1 beta.
        Am J Psychiatry. 1993; 150: 1189-1193
        • Maes M
        • Bosmans E
        • Suy E
        • Vandervorst C
        • DeJonckheere C
        • Minner B
        • et al.
        Depression-related disturbances in mitogen-induced lymphocyte responses, interleukin-1β, and soluble interleukin-2-receptor production.
        Acta Psychiatr Scand. 1991; 84: 379-386
        • Maes M
        • Lambrechts J
        • Bosmans E
        • Jacobs J
        • Suy E
        • Vandervorst C
        • et al.
        Evidence for a systemic immune activation during depression.
        Psychol Med. 1992; 22: 45-53
        • Maes M
        • Meltzer H.Y
        • Bosmans E
        • Bergmans R
        • Vandoolaeghe E
        • Ranjan R
        • et al.
        Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression.
        J Affect Disord. 1995; 34: 301-309
        • Maes M
        • Song C
        • Lin A
        • De Longh R
        • Van Gastel A
        • Kenis G
        • et al.
        The effects of psychological stress on humans.
        Cytokine. 1998; 10: 313-318
        • Maes M
        • Stevens W.J
        • Peeters D
        • DeClerck L.S
        • Bridts C.H
        • Schotte C
        • et al.
        Significantly increased expression of T-cell activation markers (interleukin-2 and HLA-DR) in depression.
        Prog Psychopharmacol Biol Psychiatry. 1993; 17: 241-255
        • Maes M
        • Vandoolaeghe E
        • Ranjan R
        • Bosmans E
        • Bergmans R
        • Desnyder R
        Increased serum interleukin-1-receptor-antagonist concentrations in major depression.
        J Affect Disord. 1995; 36: 29-36
        • Maier S.F
        • Watkins L.R
        Cytokines for psychologists.
        Psychol Rev. 1998; 105: 83-107
        • Montgomery S.A
        • Asberg M
        A new depression scale designed to be sensitive to change.
        Br J Psychiatry. 1979; 134: 382-389
        • Mullar N
        • Ackenheil M
        Psychoneuroimmunology and the cytokine action in the CNS.
        Prog Neuropsychopharmacol Biol Psychiatry. 1998; 22: 1-33
        • Massberger L
        • Traskman-Bendz L
        Increased soluble interleukin-2 receptor concentrations in suicide attempts.
        Acta Psychiatr Scand. 1993; 88: 48-52
        • Ravindran A.V
        • Anisman H
        • Merali Z
        • Charbonneau Y
        • Telner J
        • Bialik R
        • et al.
        Treatment of primary dysthymia with cognitive therapy and pharmacotherapy.
        Am J Psychiatry. 1999; 156: 1608-1617
        • Ravindran A.V
        • Griffiths J
        • Merali Z
        • Anisman H
        Lymphocyte subsets in major depression and dysthymia.
        Psychosom Med. 1995; 57: 555-563
        • Ravindran A.V
        • Griffiths J
        • Merali Z
        • Anisman H
        Primary dysthymia.
        J Affect Disord. 1996; 40: 73-84
        • Ravindran A.V
        • Merali Z
        • Anisman H
        in: Licinio J Bolis C.L Gold P Dysthymia From Clinical Neuroscience to Treatment. World Health Organization, Geneva1997: 21-44
      1. Ravindran AV, Wiseman R (1997, May): A double-blind placebo-controlled study of sertraline in the treatment of dysthymic outpatients without major depression. Presented at the conference of the American Psychiatric Association, San Diego.

        • Seidel A
        • Artolt V
        • Hunstiger M
        • Rink L
        • Behnisch A
        • Kirschner H
        Cytokine production and serum proteins in depression.
        Scand J Immunol. 1995; 41: 534-538
      2. Sheehan D, Lecrubier Y, Janavs J, Knapp E, Weiller E, Sheehan M, et al (1992): Mini-international Neuropsychiatric Interview, Clinician Rated, version 2.1. Tampa: University of South Florida Institute for Research in Psychiatry.

        • Sluzewska A
        • Rybakowski J.K
        • Bosmans E
        • Sobieska M
        • Berghmans R
        • Maes M
        • et al.
        Indicators of immune activation in major depression.
        Psychiatry Res. 1996; 64: 161-167
        • Sluzewska A
        • Rybakowski J.K
        • Laciak M
        • Mackiewicz A
        • Sobieska M
        • Wiktorowicz K
        Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine.
        Ann N Y Acad Sci. 1995; 762: 474-476
        • Szadoczky E
        • Sazekas I
        • Rihmer Z
        • Arato M
        The role of psychosocial and biological variables in seperating chronic and non-chronic major depression and early-late onset dysthymia.
        J Affect Disord. 1994; 32: 1-11
        • Thase M.E
        • Fava M
        • Halbreich U
        • Kocsis J.H
        • Koran L
        • Davidson J
        A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia.
        Arch Gen Psychiatry. 1996; 53: 777-784
        • Tilders F.J.H
        • Schmidt E.D
        Interleukin-1-induced plasticity of hypothalamic CRH neurons and long-term stress hyperresponsiveness.
        Ann N Y Acad Sci. 1998; 840: 65-73